US50015M1099 - Common Stock
KODIAK SCIENCES INC
NASDAQ:KOD (5/8/2024, 2:23:20 PM)
3.815
-0.17 (-4.15%)
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. The company is headquartered in Palo Alto, California and currently employs 116 full-time employees. The company went IPO on 2018-10-04. The firm has developed a technology platform for retinal medicines. The firm is engaged in preventing and treating the major causes of blindness by developing and commercializing next-generation therapeutics for chronic, high-prevalence retinal diseases. The Company’s ABC Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. The Company’s product candidate, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including diabetic eye diseases, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its KSI-501 is a dual inhibitor antibody biopolymer conjugate targeting both VEGF (VEGF-trap) and IL-6 (anti-IL-6 antibody) for the treatment of retinal diseases.
KODIAK SCIENCES INC
1200 Page Mill Rd
Palo Alto CALIFORNIA 94304
P: 16502810850
CEO: Victor Perlroth
Employees: 116
Website: https://kodiak.com/
Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile....
KOD stock results show that Kodiak Sciences missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kodiak Sciences (NASDAQ:KOD) just reported results for the fourth quarter of 20...
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection...
/PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative...
Here you can normally see the latest stock twits on KOD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: